Protea Biosciences Group, Inc. 4
4 · Protea Biosciences Group, Inc. · Filed Apr 4, 2017
Insider Transaction Report
Form 4
SEGAL SCOTT
Director
Transactions
- Other
Common Stock
2017-03-24+1,000,000→ 3,633,844 total - Other
Class A Warrant (right to buy)
2017-03-24+1,000,000→ 2,916,972 totalExercise: $0.09From: 2017-03-24Exp: 2018-09-24→ Common Stock (1,000,000 underlying) - Other
Class B Warrant (right to buy)
2017-03-24+1,000,000→ 2,916,972 totalExercise: $0.11From: 2017-03-24Exp: 2022-03-24→ Common Stock (1,000,000 underlying)
Footnotes (3)
- [F1]Mr. Segal held $75,000 of outstanding principal indebtedness and accrued unpaid interest of the Issuer ("Unsecured Debt"). On March 24, 2017, Mr. Segal exchanged $75,000 of Unsecured Debt of the Issuer, for units of the Issuer's equity securities, consisting of (a) an aggregate of 1,000,000 shares of common stock, $0.0001 par value per share, of the Issuer ("Common Stock") valued at $0.075 per share, (b) 18 month Class A warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.09 per share, and (c) five year Class B warrants to purchase another 1,000,000 shares at an exercise price of $0.1125 per share.
- [F2]The shares of Common Stock reported in Column 5 and 7 are the number of shares of Common Stock issuable upon exercise of the Class A Warrant and/or Class B Warrant (collectively, "Warrants").
- [F3]Includes 2,500,305 shares of Common Stock to be acquired upon the exercise of warrants and 416,667 shares of common stock to be acquired upon the exercise of stock options.